Medicare will cover weight-loss drugs

Medicare will cover weight-loss drugs under a new deal with drugmakers Eli Lilly and Novo Nordisk. Approximately 10 percent of Medicare enrollees who meet certain medical criteria, such as a diagnosis of obesity or related health conditions, will be eligible for coverage of GLP-1, Ozempic, and Zepbound. Novo Nordisk stated the expanded Medicare coverage will be available through a pilot program. Maya Goldman, writing for Axios, reports on this new Medicare coverage. Read Ms. Goldman’s article here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.